# Oncimmune Holdings EarlyCDT® lung blood test featured on ITV News

- Link: https://www.directorstalkinterviews.com/oncimmune-holdings-earlycdt-lung-blood-test-featured-on-itv-news/412850416
- Published: 2020-08-10T07:14:29+01:00
- Author: Giles Arbor

**Oncimmune Holdings plc** (LON:ONC), the leading global immunodiagnostics group,
has noted the national ITV News^(1) feature last weekend on Oncimmune’s EarlyCDT
^(®) Lung blood test titled “New Blood Test Provides Breakthrough in Lung Cancer
Detection Rates”.

The news feature highlighted that, in the UK, more than 35,000 people die of lung
cancer each year and most have their lung cancer diagnosed late thereby lowering
their chances of survival. Oncimmune’s pioneering new lung cancer blood test enables
lung cancer to be detected early which means clinicians can treat the disease and
save lives.

Oncimmune’s technology focuses on identifying the immune system’s response to the
presence of lung cancer. The body produces antibodies which, if detected by Oncimmune’s
blood test, enables clinicians to focus their diagnosis on identifying the disease
and treating it earlier than current clinical practice.

The news article noted that Oncimmune’s EarlyCDT Lung blood test has received a 
Medtech Innovation Briefing (“MIB”) from the UK’s National Institute for Health 
and Care Excellence (“NICE”). NICE reviewed EarlyCDT Lung for cancer risk stratification
of indeterminate pulmonary nodules (“IPNs”). The briefing, intended to support NHS
commissioners and staff who are considering using new medical or diagnostic technologies,
states that EarlyCDT Lung enables earlier and accurate diagnosis of lung cancer 
in high risk patients which could mean intervention is offered early, with the potential
benefit of early treatment and improved outcomes. The MIB also notes that this could
have a wider benefit by saving other NHS resources (CT scanning and radiologists)
and reducing waiting times.

The ITV news report concluded by saying that “the test has been recommended for 
use in the NHS and, if given full approval, many more patients could benefit from
screening for this deadly disease.”

> **Adam M Hill, CEO of Oncimmune Holdings said:**_ “We are delighted that Oncimmune’s
> EarlyCDT Lung blood test has received such international publicity. The benefits
> of offering patients the opportunity to identify lung cancer early are clear –
> early detection of this disease saves lives. We are actively engaged across the
> NHS to bring the blood test to clinicians and patients.”_

^(1) https://www.itv.com/news/2020-08-08/new-blood-test-provides-breakthrough-in-
lung-cancer-detection-rates

Share on:
